Drugs

Coalition follow-up letter to FDA regarding FDA overruling their own scientists
The Coalition expressed our strong concerns when the Food and Drug Administration (FDA) Center Directors...
Coalition Letter to Senator braun regarding the Promising Pathways Act
The Promising Pathways Act has no safeguards for protecting patients from drugs that have no benefits....
Coalition Comments to FDA on their Guidance for Best Practices for Selecting a Predicate Device to Support a Premarket Notification [510(k)] Submission
In its public comment, members of the Patient, Consumer, Public Health Coalition told FDA that if a predicate...
Coalition comments Regarding the FDA Draft Guidance Recommendations for the Use of Clinical Data in Premarket Notification [510(k)] Submissions
In its public comment, members of the Patient, Consumer, Public Health Coalition urged FDA to rely more...
Coalition Comments on the FDA Proposed Rule Regarding Laboratory Developed Tests
The Coalition supported the FDA proposed rule on lab-developed tests (LDTs) to diagnose diseases and...
Coalition Letter to FDA regarding consumer representatives in Advisory Committees
The Coalition expressed concerns that patients, health professionals, and industry-affiliated individuals...
Coalition letter to HHS and CMS Regarding the CMS Registry for Alzheimer's Treatments
It is essential that all data collected by any of the registries are made publicly available for research...
Coalition Letter to FDA Commissioner Califf Regarding FDA Advisory Committee Meetings
The Coalition expressed our strong concerns when the Food and Drug Administration (FDA) Center Directors...
Coalition comment to CMS on on CT Quality Measures Included in the Proposed Rule for the Hospital Inpatient Quality Reporting (IQR) Program
We support this CT quality measure because it establishes a floor and a ceiling to provide an optimal...
Meeting of Patient, Consumer, and Public Health Coalition with Commissioner Califf and Key FDA Officials
The Patient, Consumer, and Public Health Coalition, scheduled a hybrid meeting with FDA Commissioner...
February 10, 2022

Public Comments to CMS on Aduhelm for the treatment of Alzheimer’s disease

Patient, Consumer, and Public Health Coalition provides public comments on Aduhelm and similar medical products for the treatment of Alzheimer’s disease

Marketing Instructor

Bruce Stevens

Duis aute irure dolor in velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat voluptas.

WordPress Instructor

Michelle Baker

Duis aute irure dolor in velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat voluptas.

JavaScript Instructor

Paul Santos

Duis aute irure dolor in velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat voluptas.

Marketing Instructor

Donna Carroll

Duis aute irure dolor in velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat voluptas.

PHP Instructor

Scott Valdez

Duis aute irure dolor in velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat voluptas.